APA (7th ed.) Citation

Saiag, P., Gutzmer, R., Ascierto, P. A., Maio, M., Grob, J. -., Murawa, P., . . . Therasse, P. (2016). Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). Annals of oncology, 27(10), . https://doi.org/10.1093/annonc/mdw291

Chicago Style (17th ed.) Citation

Saiag, Philippe, et al. "Prospective Assessment of a Gene Signature Potentially Predictive of Clinical Benefit in Metastatic Melanoma Patients Following MAGE-A3 Immunotherapeutic (PREDICT)." Annals of Oncology 27, no. 10 (2016). https://doi.org/10.1093/annonc/mdw291.

MLA (9th ed.) Citation

Saiag, Philippe, et al. "Prospective Assessment of a Gene Signature Potentially Predictive of Clinical Benefit in Metastatic Melanoma Patients Following MAGE-A3 Immunotherapeutic (PREDICT)." Annals of Oncology, vol. 27, no. 10, 2016, https://doi.org/10.1093/annonc/mdw291.